ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 1541.HK files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 15.54% | 30.00% | Pass |
| Interest-bearing investments | 65.23% | 30.00% | Fail |
| Non-permissible income | 4.43% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.04% | 33.00% | Pass |
| Interest-bearing investments | 92.50% | 33.00% | Fail |
| Non-liquid assets | 7.50% | at least 20.00% | Fail |
| Non-permissible income | 4.43% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.04% | 33.33% | Pass |
| Cash + interest-bearing securities | 92.50% | 33.33% | Fail |
| Accounts receivable | 92.50% | 33.33% | Fail |
| Non-permissible income | 4.43% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.04% | 33.33% | Pass |
| Cash + interest-bearing securities | 92.50% | 33.33% | Fail |
| Accounts receivable | 92.50% | 50.00% | Fail |
| Non-permissible income | 4.43% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.78% | 33.00% | Pass |
| Cash + interest-bearing securities | 32.65% | 33.00% | Pass |
| Accounts receivable | 0.00% | 33.00% | Pass |
| Non-permissible income | 4.43% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.98% | 33.00% | Pass |
| Cash + interest-bearing securities | 20.90% | 49.00% | Pass |
| Accounts receivable | 0.00% | 49.00% | Pass |
| Non-permissible income | 4.43% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.98% | 33.33% | Pass |
| Cash + interest-bearing securities | 20.90% | 33.33% | Pass |
| Accounts receivable | 20.90% | 49.00% | Pass |
| Non-permissible income | 4.43% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.50 | NEUTRAL |
| Stochastic %K (14) | 5.58 | BUY |
| CCI (20) | -150.00 | BUY |
| Williams %R (14) | -94.42 | BUY |
| MACD (12,26,9) | -0.05 | SELL |
| ROC (10) | -13.61 | SELL |
| Momentum (10) | -0.51 | SELL |
| EMA (10) | 3.43 | SELL |
| SMA (10) | 3.47 | SELL |
| EMA (20) | 3.47 | SELL |
| SMA (20) | 3.53 | SELL |
| EMA (30) | 3.47 | SELL |
| SMA (30) | 3.45 | SELL |
| EMA (50) | 3.51 | SELL |
| SMA (50) | 3.43 | SELL |
| EMA (100) | 3.88 | SELL |
| SMA (100) | 3.64 | SELL |
| EMA (200) | 5.19 | SELL |
| SMA (200) | 4.54 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase Ib/II clinical trial to treat solid tumors; and IMM2520, which is in Phase I clinical trial for solid tumors. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.